Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2021 | 467 | 0.940 |
Why?
|
| Oncologists | 4 | 2022 | 9 | 0.800 |
Why?
|
| Neoplasms | 8 | 2023 | 1660 | 0.530 |
Why?
|
| Cranial Irradiation | 2 | 2014 | 8 | 0.520 |
Why?
|
| Lung Neoplasms | 8 | 2018 | 1172 | 0.490 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2015 | 300 | 0.490 |
Why?
|
| Geriatric Assessment | 5 | 2022 | 107 | 0.480 |
Why?
|
| Chemoradiotherapy | 4 | 2018 | 54 | 0.450 |
Why?
|
| Radiation Injuries | 3 | 2018 | 97 | 0.420 |
Why?
|
| Prostatic Neoplasms | 6 | 2015 | 778 | 0.400 |
Why?
|
| Dacarbazine | 1 | 2010 | 32 | 0.390 |
Why?
|
| Aged | 35 | 2023 | 14842 | 0.370 |
Why?
|
| Quality of Life | 7 | 2021 | 1515 | 0.360 |
Why?
|
| Caregivers | 3 | 2021 | 365 | 0.310 |
Why?
|
| Melanoma | 1 | 2010 | 335 | 0.290 |
Why?
|
| Brain Neoplasms | 1 | 2010 | 371 | 0.290 |
Why?
|
| Skin Neoplasms | 1 | 2010 | 375 | 0.280 |
Why?
|
| Breast Neoplasms | 5 | 2016 | 1533 | 0.260 |
Why?
|
| Aged, 80 and over | 18 | 2021 | 4843 | 0.260 |
Why?
|
| Middle Aged | 31 | 2019 | 21119 | 0.250 |
Why?
|
| Hot Flashes | 3 | 2010 | 8 | 0.250 |
Why?
|
| Medical Oncology | 2 | 2022 | 110 | 0.210 |
Why?
|
| Humans | 43 | 2023 | 68525 | 0.210 |
Why?
|
| Vitamin E | 2 | 2015 | 55 | 0.210 |
Why?
|
| Male | 30 | 2023 | 37281 | 0.210 |
Why?
|
| Treatment Outcome | 15 | 2021 | 7028 | 0.200 |
Why?
|
| Abiraterone Acetate | 1 | 2021 | 2 | 0.200 |
Why?
|
| Female | 31 | 2023 | 38015 | 0.200 |
Why?
|
| Survivors | 3 | 2015 | 254 | 0.200 |
Why?
|
| Academic Medical Centers | 2 | 2014 | 281 | 0.200 |
Why?
|
| Disease-Free Survival | 7 | 2021 | 349 | 0.200 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2021 | 32 | 0.190 |
Why?
|
| Health Education | 2 | 2014 | 279 | 0.190 |
Why?
|
| Patient Selection | 2 | 2016 | 592 | 0.190 |
Why?
|
| Double-Blind Method | 9 | 2018 | 1737 | 0.190 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2019 | 2 | 0.180 |
Why?
|
| Antioxidants | 2 | 2015 | 304 | 0.180 |
Why?
|
| Colonic Neoplasms | 2 | 2015 | 299 | 0.170 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 4 | 0.170 |
Why?
|
| Lisinopril | 1 | 2018 | 16 | 0.170 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2010 | 37 | 0.170 |
Why?
|
| Mometasone Furoate | 2 | 2016 | 2 | 0.170 |
Why?
|
| Immunotherapy | 1 | 2019 | 212 | 0.160 |
Why?
|
| Diarrhea | 2 | 2016 | 63 | 0.150 |
Why?
|
| Carboplatin | 5 | 2015 | 59 | 0.150 |
Why?
|
| Selenomethionine | 2 | 2015 | 8 | 0.150 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 1070 | 0.150 |
Why?
|
| Carcinoma, Small Cell | 2 | 2007 | 53 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 261 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2011 | 444 | 0.140 |
Why?
|
| Surveys and Questionnaires | 5 | 2018 | 2798 | 0.140 |
Why?
|
| Sulfasalazine | 1 | 2016 | 3 | 0.140 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2008 | 99 | 0.140 |
Why?
|
| Survival Analysis | 4 | 2015 | 714 | 0.140 |
Why?
|
| Cooperative Behavior | 2 | 2016 | 235 | 0.140 |
Why?
|
| Pelvis | 1 | 2016 | 38 | 0.140 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2015 | 35 | 0.140 |
Why?
|
| Drug Administration Schedule | 4 | 2010 | 567 | 0.140 |
Why?
|
| Adult | 19 | 2021 | 21375 | 0.140 |
Why?
|
| Adenomatous Polyps | 1 | 2015 | 18 | 0.140 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2015 | 41 | 0.130 |
Why?
|
| Paclitaxel | 5 | 2015 | 140 | 0.130 |
Why?
|
| Combined Modality Therapy | 4 | 2015 | 951 | 0.130 |
Why?
|
| Boronic Acids | 2 | 2015 | 40 | 0.130 |
Why?
|
| Pyrazines | 2 | 2015 | 46 | 0.130 |
Why?
|
| Residence Characteristics | 2 | 2019 | 252 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 2 | 2014 | 561 | 0.130 |
Why?
|
| Patient Care | 1 | 2015 | 61 | 0.130 |
Why?
|
| Colonic Polyps | 1 | 2015 | 63 | 0.130 |
Why?
|
| Medically Uninsured | 1 | 2015 | 99 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2016 | 285 | 0.130 |
Why?
|
| Terminology as Topic | 1 | 2015 | 141 | 0.130 |
Why?
|
| Doxepin | 1 | 2014 | 5 | 0.120 |
Why?
|
| Stomatitis | 1 | 2014 | 8 | 0.120 |
Why?
|
| Facial Pain | 1 | 2014 | 8 | 0.120 |
Why?
|
| Communication | 3 | 2022 | 329 | 0.120 |
Why?
|
| Cancer Survivors | 1 | 2016 | 145 | 0.120 |
Why?
|
| Administration, Oral | 3 | 2010 | 411 | 0.120 |
Why?
|
| Poverty | 1 | 2015 | 218 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 148 | 0.120 |
Why?
|
| Acute Pain | 1 | 2014 | 35 | 0.120 |
Why?
|
| Deoxycytidine | 4 | 2007 | 83 | 0.120 |
Why?
|
| Cataract Extraction | 1 | 2015 | 127 | 0.120 |
Why?
|
| Survival Rate | 5 | 2008 | 1055 | 0.120 |
Why?
|
| Healthcare Disparities | 2 | 2015 | 378 | 0.120 |
Why?
|
| Cataract | 1 | 2015 | 134 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2015 | 311 | 0.110 |
Why?
|
| Community Networks | 1 | 2014 | 96 | 0.110 |
Why?
|
| Analgesics | 1 | 2014 | 118 | 0.110 |
Why?
|
| Prognosis | 5 | 2021 | 2093 | 0.110 |
Why?
|
| Camptothecin | 3 | 2007 | 39 | 0.110 |
Why?
|
| Neoplasm Staging | 6 | 2015 | 799 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 848 | 0.110 |
Why?
|
| Telephone | 2 | 2016 | 160 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2010 | 536 | 0.100 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2011 | 32 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 560 | 0.100 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2011 | 73 | 0.100 |
Why?
|
| Menopause | 2 | 2008 | 47 | 0.100 |
Why?
|
| Pregnadienediols | 1 | 2010 | 1 | 0.100 |
Why?
|
| Pilot Projects | 4 | 2018 | 1341 | 0.100 |
Why?
|
| Radiodermatitis | 1 | 2010 | 8 | 0.100 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 125 | 0.090 |
Why?
|
| Amitriptyline | 1 | 2010 | 11 | 0.090 |
Why?
|
| Dermatologic Agents | 1 | 2010 | 32 | 0.090 |
Why?
|
| Baclofen | 1 | 2010 | 24 | 0.090 |
Why?
|
| Carcinoma in Situ | 1 | 2010 | 45 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 61 | 0.090 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2010 | 60 | 0.090 |
Why?
|
| Ketamine | 1 | 2010 | 57 | 0.090 |
Why?
|
| Amines | 1 | 2010 | 98 | 0.090 |
Why?
|
| Risk Factors | 5 | 2023 | 5719 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 581 | 0.090 |
Why?
|
| Decision Making | 1 | 2012 | 410 | 0.080 |
Why?
|
| Aging | 1 | 2015 | 911 | 0.080 |
Why?
|
| Selenium | 1 | 2008 | 36 | 0.080 |
Why?
|
| Megestrol Acetate | 1 | 2008 | 1 | 0.080 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2010 | 208 | 0.080 |
Why?
|
| Placebos | 3 | 2018 | 195 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 44 | 0.080 |
Why?
|
| Taxoids | 2 | 2007 | 41 | 0.080 |
Why?
|
| Libido | 1 | 2007 | 7 | 0.080 |
Why?
|
| Taste Disorders | 1 | 2007 | 3 | 0.080 |
Why?
|
| Zinc Sulfate | 1 | 2007 | 4 | 0.080 |
Why?
|
| Organoplatinum Compounds | 1 | 2007 | 21 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2021 | 7264 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 4 | 2008 | 41 | 0.070 |
Why?
|
| Radiotherapy | 2 | 2018 | 86 | 0.070 |
Why?
|
| Testosterone | 1 | 2007 | 96 | 0.070 |
Why?
|
| Thalidomide | 1 | 2006 | 24 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 3256 | 0.070 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2006 | 74 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 2 | 2021 | 138 | 0.070 |
Why?
|
| Cyclohexanols | 1 | 2006 | 12 | 0.070 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2006 | 9 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2008 | 331 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2005 | 41 | 0.070 |
Why?
|
| Counseling | 1 | 2007 | 279 | 0.060 |
Why?
|
| Anxiety | 2 | 2020 | 422 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2010 | 2356 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2005 | 138 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2010 | 2004 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 424 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2021 | 3702 | 0.060 |
Why?
|
| Focus Groups | 2 | 2016 | 247 | 0.060 |
Why?
|
| Depression | 2 | 2021 | 942 | 0.060 |
Why?
|
| Bortezomib | 2 | 2015 | 45 | 0.060 |
Why?
|
| South Carolina | 3 | 2015 | 2750 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 475 | 0.050 |
Why?
|
| Drug Combinations | 2 | 2015 | 304 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2005 | 332 | 0.050 |
Why?
|
| Acute Disease | 2 | 2016 | 658 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 319 | 0.050 |
Why?
|
| Prednisone | 1 | 2021 | 104 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1465 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2007 | 824 | 0.050 |
Why?
|
| Uncertainty | 1 | 2020 | 31 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 766 | 0.050 |
Why?
|
| Administration, Cutaneous | 2 | 2010 | 56 | 0.040 |
Why?
|
| Dyspnea | 1 | 2018 | 87 | 0.040 |
Why?
|
| Mental Health | 1 | 2020 | 278 | 0.040 |
Why?
|
| United States | 4 | 2015 | 7335 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 201 | 0.040 |
Why?
|
| Hospitalization | 1 | 2023 | 977 | 0.040 |
Why?
|
| Patient Safety | 1 | 2018 | 202 | 0.040 |
Why?
|
| Enteritis | 1 | 2016 | 6 | 0.040 |
Why?
|
| Time Factors | 2 | 2015 | 4655 | 0.040 |
Why?
|
| Culture | 1 | 2016 | 75 | 0.040 |
Why?
|
| Cancer Care Facilities | 1 | 2015 | 32 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2015 | 108 | 0.030 |
Why?
|
| Computers, Handheld | 1 | 2015 | 44 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 729 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 114 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2015 | 82 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2015 | 117 | 0.030 |
Why?
|
| Mouthwashes | 1 | 2014 | 9 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2015 | 156 | 0.030 |
Why?
|
| Young Adult | 2 | 2015 | 5708 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1860 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 2264 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 238 | 0.030 |
Why?
|
| Lung | 1 | 2018 | 849 | 0.030 |
Why?
|
| Self Report | 1 | 2015 | 370 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 260 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2016 | 403 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2015 | 339 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2015 | 284 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 730 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2014 | 328 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 791 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2015 | 326 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2011 | 44 | 0.020 |
Why?
|
| Prevalence | 1 | 2015 | 1609 | 0.020 |
Why?
|
| Lecithins | 1 | 2010 | 1 | 0.020 |
Why?
|
| Pruritus | 1 | 2010 | 35 | 0.020 |
Why?
|
| GABA-B Receptor Agonists | 1 | 2010 | 5 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1582 | 0.020 |
Why?
|
| Poloxamer | 1 | 2010 | 10 | 0.020 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2010 | 20 | 0.020 |
Why?
|
| Gels | 1 | 2010 | 55 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2077 | 0.020 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2010 | 128 | 0.020 |
Why?
|
| alpha-Tocopherol | 1 | 2008 | 5 | 0.020 |
Why?
|
| Adolescent | 2 | 2015 | 8903 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2010 | 234 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 6 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2008 | 10 | 0.020 |
Why?
|
| Vidarabine | 1 | 2008 | 12 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 33 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2008 | 62 | 0.020 |
Why?
|
| Rituximab | 1 | 2008 | 61 | 0.020 |
Why?
|
| Leucovorin | 1 | 2007 | 35 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 151 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 129 | 0.020 |
Why?
|
| Topotecan | 1 | 2006 | 17 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2007 | 82 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2007 | 130 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1054 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 100 | 0.020 |
Why?
|
| Neutropenia | 1 | 2006 | 72 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2006 | 242 | 0.020 |
Why?
|
| Probability | 1 | 2006 | 244 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 334 | 0.020 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2006 | 42 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2007 | 392 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2007 | 179 | 0.020 |
Why?
|
| Nausea | 1 | 2005 | 47 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 369 | 0.020 |
Why?
|
| Vomiting | 1 | 2005 | 56 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 510 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 125 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 107 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 122 | 0.020 |
Why?
|
| Thoracotomy | 1 | 2004 | 25 | 0.020 |
Why?
|
| Mediastinum | 1 | 2004 | 39 | 0.020 |
Why?
|
| Fatigue | 1 | 2005 | 132 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 648 | 0.020 |
Why?
|
| Pneumonectomy | 1 | 2004 | 79 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2007 | 447 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2004 | 274 | 0.010 |
Why?
|
| Etoposide | 1 | 2003 | 64 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2004 | 258 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1745 | 0.010 |
Why?
|
| Cisplatin | 1 | 2003 | 192 | 0.010 |
Why?
|
| Disease Progression | 1 | 2005 | 1037 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2004 | 1615 | 0.010 |
Why?
|